Patient with candida krusei infection in matinas biopharma's oral mat2203 expanded access program achieves complete clinical resolution

Bedminster, n.j., oct. 11, 2023 (globe newswire) -- matinas biopharma (nyse american: mtnb), a clinical-stage biopharmaceutical company focused on delivering groundbreaking therapies using its lipid nanocrystal (lnc) platform delivery technology, announces complete clinical resolution of a patient's recurrent hemorrhagic cystitis due to candida krusei (c. krusei), a fluconazole inherited resistant fungal pathogen, following treatment with mat2203, matinas' oral formulation of the potent antifungal amphotericin b. this patient was treated under matinas' expanded access/compassionate use program by marisa h. miceli, md, professor of medicine, specializing in fungal infections and transplant diseases, division of infectious diseases, internal medicine, at the university of michigan.
MTNB Ratings Summary
MTNB Quant Ranking